Friday Mar 7
Susquehanna Increases Valeant Pharmaceuticals Int Price Target to $170.00
BVF has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets raised their price target on shares of Valeant Pharmaceuticals Int from $162.00 to $164.00 in a research note on Friday, February 28th.
Valeant Pharmaceuticals International Donates $250,000 To The
The donation is a reflection of Valeant's ongoing support and commitment to the wellbeing of women, and is the first of four checks the company will present to NCADV in a one year period for a combined donation goal of "NCADV is thrilled to be working with Valeant as a partner in our efforts to end violence in the home," said , Executive Director ... (more)
Valeant Pharmaceuticals Intl Price Target Raised to $158.00 at RBC Capital
The firm currently has an "outperform" rating on the stock. RBC Capital's target price points to a potential upside of 10.20% from the company's current price.
Ubs Ag Increases Valeant Pharmaceuticals Intl Price Target to $170.00
The firm currently has a "buy" rating on the stock. UBS AG's price objective would indicate a potential upside of 14.86% from the stock's previous close.
Canada Stocks-TSX opens higher as Valeant, TD drive gains
Canada's main stock index opened higher on Thursday, supported by gains in Valeant Pharmaceuticals International Inc and Toronto Dominion Bank after the companies reported quarterly results.
Nanaimo Daily News
Valeant Pharmaceuticals nets $124 million in Q4, or 36 cents per diluted share
Valeant Pharmaceuticals International Inc. is reporting net income of $124 million for the fourth quarter of 2013, or 36 cents per diluted share.
Canada Stocks Top Among Biggest Markets on Gold Surge
Canadian stocks are beating the world's biggest markets this year, as a surge among gold miners propels the benchmark equity gauge toward a five-year high.
Nehal Chopra's Ratan Capital is Betting on These Stocks
Nehal Chopra is a graduate from the Wharton School of the University of Pennsylvania.
Valeant Pharmaceuticals PT Raised to $162.00
BMO Capital Markets' price objective indicates a potential upside of 10.60% from the stock's previous close.
Valeant Pharmaceuticals Sets New 52-Week High at $142.20
Shares of Valeant Pharmaceuticals reached a new 52-week high during trading on Tuesday , AnalystRatingsNetwork reports.